Redeye keeps its Base Case and forecasts unchanged.
Redeye is encouraged by yesterday’s announcement that Powercell has received another major order fro...
Q3 report due 25 October We forecast SEK 551m net sales, SEK 83m EBITA We reiterate fair value range...
Aptahem har gjort stora framsteg med läkemedelskandidaten Apta-1 för behandling av svåra inflammator...
Clean Motion AB utvecklar hållbara transportlösningar för städer, med fokus på att minska koldioxidu...
Redeye leaves a brief comment on today's news that Genovis' has launched the second generation of it...
Redeye comments on Active Biotech’s rights issue of SEK35m with a subscription price of SEK 0.
As discussed in our previous update, Crunchfish has now settled on a path forward for the company's ...
Vi inleder bevakning på Premium Snacks Nordic AB, ett svenskt bolag som utvecklar, tillverkar och sä...
Redeye endorses that the FDA has provided positive guidance regarding generic substitutability for I...
Redeye provides a brief comment on Xspray following yesterday's confirmation of the anticipated Q4 2...
Presented a clear and detailed operating blueprint SEK 3.
Mangold uppdaterar sin syn på mobiloperatören My Beat efter det första kvartalet.
Redeye does not believe the underlying value of Hexatronic is 10% less due to Larsson Lyon leaving.
Redeye provides a longer note following WntResearch’s failed phase 2 study and CEO interview.
